Trial Profile
A Randomized, Double-blind, Placebo-Controlled Trial To Evaluate The Safety And Immunogenicity Of LFnp24B.C, a Therapeutic HIV Vaccine,in HIV-infected Chinese Patients Receiving Stable ART treatment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Sep 2016
Price :
$35
*
At a glance
- Drugs LFn-p24-B-C (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Haikou VTI Biological Institute
- 19 Apr 2016 Status changed from not yet recruiting to completed according to the Chinese Clinical Trial Register record.
- 04 Jun 2014 New trial record